Multicenter Evaluation of SonoVue for Improved Endocardial Border Delineation

Nanda, Navin C.; Wistran, Daniel; Karlsberg, Ronald P.; Hack, Terrence C.; Smith, William B.; Foley, David A.; Picard, Michael H.; Cotter, Bruno

doi:10.1046/j.1540-8175.2002.00027.x

Cited by 42 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a multicentric trial evaluated the efficacy of Sono Vue (Bracco Diagnostics Inc., Princeton, NJ) and compared it with Albunex and agitated saline. Complete LV opacification was seen in 34%-87% of cases receiving SonoVue compared to 0%-16% of Albunex receiving patients [22]. These studies clearly establish the superiority of second-generation agents and are currently recommended for enhancing the delineation of endocardial borders in patients with sub-optimal images.…”

Section: Contrast Agentsmentioning

confidence: 64%

Contrast Echocardiography for Left Ventricular Opacification

Eleid

Khandheria²,

Sengupta³

2004

Contrast Echocardiography in Clinical Practice

View full text Add to dashboard Cite

Accurate assessment of left ventricular (LV) function is of paramount importance in clinical cardiology. Although the LV contraction and relaxation occur in a complex threedimensional format, changes in two-dimensional regional and global LV geometry during a cardiac cycle provide a reliable estimate of the overall LV function. This information is obtained comprehensively during realtime two-dimensional echocardiography by quantifying the extent of wall thickening, endocardial motion and serial changes in LV sizes and volumes. Accurate echo cardiographic interpretation, however, necessitates a proper delineation of the blood-endocardial interface and is not found adequately in a significant proportion (10%-20%) of patients referred for routine echocardiographic evaluation in clinical practice [ 1]. Suboptimal image quality in these patients results from a variety of factors including obesity, lung disease or chest wall deformities, thereby obviating an optimal application and utilization of cardiac ultrasound. Alternate techniques have emerged in the last decade for improving the diagnostic yield of echocardiography in such patients and include modalities like tissue harmonic imaging, contrast echocardiography and Doppler imaging for myocardial motion [2][3][4][5][6][7]. This chapter highlights the concepts and application of intravenous contrast for LV opacification, its clinical utility and relative merits in assessing structural and functional abnormalities of the left ventricle. Concepts and TechniqueGas bubbles interact complexly with incident ultrasound beams. Ultrasonic waves not only get reflected at the gas-liquid interface but are also modified in amplitude and frequency due to rapid bubble oscillations [8,9]. The ultrasound beam therefore encounters a wider scattering and frequency modulation with contrast agents than red-blood cells and hence echoes returning from bubbles effectively delineate the blood pool-endocardial interface [8,9]. J. L. Zamorano et al., Contrast Echocardiography in Clinical Practice

show abstract

Section: Contrast Agentsmentioning

confidence: 64%

Contrast Echocardiography for Left Ventricular Opacification

Eleid

Khandheria²,

Sengupta³

2004

Contrast Echocardiography in Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Such contrast agents which are poorly soluble, do not undergo metabolism, and remain totally in the intravascular space, are eliminated during expiration. In the literature the incidence of side effects is low (0.01%), mainly limited to allergic reactions [17, 18]. Non-renal elimination is of great importance in patients with kidney disease, however there is a little experience in this population.…”

Section: Discussionmentioning

confidence: 99%

“…EICA were initially applied for improving assessment of left ventricular function (left ventricle opacification, endocardial border delineation [18, 19]. Recently this technique was applied for perfusion exploration, particularly after myocardial infarction [20].…”

Section: Discussionmentioning

confidence: 99%

Application of Myocardial Contrast Echocardiography for the Perfusion Assessment in Patients with End-Stage Renal Failure – Comparison with Coronary Angiography

Sobkowicz

Tomaszuk‐Kazberuk²,

Kralisz³

et al. 2008

Am J Nephrol

View full text Add to dashboard Cite

“…However, in spite of more persisting contrast on the arterial side of the heart with SHU 508 [9], it is not in clinical use to study early reduced blood flow in the myocardium using MCE. Since preformed, lyophilized phospholipid-stabilized gas bubbles on the market have been a success [10], the simplicity of the gas-releasing carbohydrate-based products in the form of a dry, particulate, water-soluble precursor of gas bubbles encouraging further research. In the present research, our first aim was to investigate if lifetime of the populations of gas bubbles released could be prolonged, by investigating a broad range of amphiphilic compounds.…”

Section: Introductionmentioning

confidence: 99%

Stabilization of Gas Bubbles Released from Water‐Soluble Carbohydrates Using Amphiphilic Compounds: Preparation of Formulations and Acoustic Monitoring of Bubble Lifetime

Hoff

Foss²,

Dyrstad

et al. 2011

J Surfact & Detergents

View full text Add to dashboard Cite

The ultrasound contrast agents Echovist® and Levovist® (Bayer AG, Schering AG, Germany) are based on the release of gas bubbles from milled α-d-galactose. In diagnostic ultrasound, for this class of contrast agents, there is a need for prolonged contrast duration. To investigate if new carbohydrate compositions could prolong the lifetime of the gas bubbles, α-d-galactose was mixed with other carbohydrates or amphiphiles with varying log P. Acoustic attenuation vs. time (390 s) area under the curve (A390) and bubble half-time (t½) were used as measures of prolonged lifetime of gas bubbles. The products, to which 0.1% of a lipophilic carboxylic acid (5β-cholanic acid, behenic acid, and melissic acid) has been added, showed more than 5, 7 and 11 times enhancement of A390, respectively, compared with the reference compound 2 (RC2) corresponding to the commercial product Levovist®. The half-time t ½ of the same compounds was prolonged more than 6 times compared with RC2. A partial least square (PLS) statistical analysis confirmed that, for additives, high log P carboxylic acids lead to the highest A390. The present results bear a promise of products with a more persistent in vivo ultrasound contrast effect than the commercially available agents.

show abstract

Multicenter Evaluation of SonoVue for Improved Endocardial Border Delineation

Abstract: SonoVue is superior to Albunex for improving visualization of endocardial borders in patients with suboptimal noncontrast echocardiograms. Optimal increases in LVEBD, LVO, and duration of useful contrast effect were observed at the 2.0 ml dose of SonoVue.

Cited by 42 publications

References 15 publications

Contrast Echocardiography for Left Ventricular Opacification

Contrast Echocardiography for Left Ventricular Opacification

Application of Myocardial Contrast Echocardiography for the Perfusion Assessment in Patients with End-Stage Renal Failure – Comparison with Coronary Angiography

Stabilization of Gas Bubbles Released from Water‐Soluble Carbohydrates Using Amphiphilic Compounds: Preparation of Formulations and Acoustic Monitoring of Bubble Lifetime

Contact Info

Product

Resources

About